Andere talen Gimv NV

Aandelen

GIMB

BE0003699130

Beleggingsbeheer & Fondsbeheerders

Beurs gesloten - Euronext Bruxelles Andere beurzen 17:55:00 21-01-2026			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
44,10 ^EUR	+0,34%		-2,11%	-1,23%

20/01	EQT Unit leidt EUR51 miljoen financieringsronde voor Exciva	MT
20/01	Gimv rondt met succes een Series B investeringsronde in Exciva van 51 miljoen euro af	AM

Andere talen

20/01	Exciva GmbH announced that it has received ?51 million in funding from a group of investors
20/01	Gimv : investit dans l'allemand Exciva avec l'objectif d'avancer dans Alzheimer
20/01	EQT Unit Co-leads EUR51 Million Funding Round for Exciva
20/01	Morning Meeting: Märkte erliegen zunehmenden Spannungen
20/01	EQT Co-Leads $59.4 Million Funding Round in Alzheimer's Specialist Exciva
20/01	Gimv completes EUR 51 mln financing round in Exciva to advance Alzheimer's therapy
20/01	Gimv : leidt een Series B investeringsronde van EUR 51 miljoen in Exciva voor verdere ontwikkeling van een innovatieve Alzheimerbehandeling
20/01	Gimv : leads € 51 million Series B investment round in Exciva to advance innovative Alzheimer’s therapy
16/01	Bourse : beau contrat pour Alstom, Equinor soulagé, OPA sur Klöckner
16/01	Gimv vend sa participation majoritaire dans ALT Technologies
16/01	Gimv Signs Deal to Divest Majority ALT Technologies Stake
16/01	La folie des puces reprend, ce qui est petit est mignon
16/01	Gimv : verkoopt meerderheidsbelang in ALT Technologies aan CCL Industries
16/01	Gimv sells majority stake in ALT Technologies to CCL Industries
16/01	Gimv : sells majority stake in ALT Technologies to CCL Industries
16/01	Gimv : sells majority stake in ALT Technologies to CCL Industries
16/01	Gimv : sells majority stake in ALT Technologies to CCL Industries
16/01	CCL Industries Inc. (TSX:CCL.B) signed a binding agreement to acquire Advanced Safety Technologies B.V. from Gimv NV and others for CAD 32 million.
12/01	Gimv : Kivu Bioscience Announces First Patient Dosed in Phase 1 Trial of KIVU-107 Next-Generation PTK7-Targeting ADC for Advanced Solid Tumors
12/01	EQT Life Sciences backs Kinaset Therapeutics' USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases
12/01	Gimv : Kinaset Therapeutics Announces $103 Million Oversubscribed Series B Financing to Advance Novel, Inhaled Therapeutic Candidate for Respiratory Diseases
10/01	Kinaset Therapeutics, Inc. announced that it has received $103 million in funding from a group of investors
09/01	Kinaset Therapeutics, Inc. announced that it expects to receive $103.187734 million in funding
08/01	Gimv : Complement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy Secondary to AMD
07/01	Mediar Therapeutics, Inc. announced that it has received $76 million in funding from a group of investors

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripten Persberichten Officiële publicaties Andere talen MarketScreener-artikels MarketScreener-analyses Ideeën voor de handel

Andere talen Gimv NV

Aandelen

GIMB

BE0003699130

Beleggingsbeheer & Fondsbeheerders

Andere talen

Filters